• The company has launched the Remsima SC- a biosimilar referencing Janssen’s Remicade (infliximab) on Apr 27- 2020. The clinical study demonstrated Remsima SC has similar results in efficacy and safety compared to the IV formulation
• The launch followed market releases of the product in Germany and the UK in Feb and Mar’2020 respectively. Before the launch in the Netherlands- the company had an online symposium- attended by 200 medical professionals on Apr 21- 2020
• Celltrion collaborated with CZ to reimburse the entire treatment fee for Remsima SC and allows patients to administer it directly at home. Additionally- CZ's SC formulation is more expensive than IV formulation- but 'Remsima SC' is expected to be a good alternative to the infliximab formulation

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: Celltrion

Related News: Celltrion’s Remsima SC (biosimilar- infliximab) Receives KFDA’s Approval for Rheumatoid Arthritis